Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

Cited by (744)

Items 201–300 of 744

1. Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases
   André Mansinho, Arlindo Rebelo Ferreira, Sandra Casimiro, Irina Alho, Inês Vendrell, Ana Lúcia Costa, Rita Sousa, Catarina Abreu, Catarina Pulido, Daniela Macedo et al. · 2019 · International Journal of Molecular Sciences
2. Molecular determinants of response to high-dose androgen therapy in prostate cancer
   Michael D. Nyquist, Alexandra N. Corella, Osama Mohamad, Ilsa M. Coleman, Arja Kaipainen, Daniel A. Kuppers, Jared M. Lucas, Patrick J. Paddison, Stephen R. Plymate, Peter S. Nelson et al. · 2019 · JCI Insight
3. SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer
   Rafael S. Martinez, Mark J. Salji, Linda K. Rushworth, Chara Ntala, Giovanny Rodriguez Blanco, Ann Hedley, William Andrew Clark, Paul Peixoto, Éric Hervouet, Elodie Renaude et al. · 2021 · Cancer Research
4. The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
   Peder R. Braadland, Håkon Ramberg, Helene Hartvedt Grytli, Alfonso Urbanucci, Heidi Kristin Nielsen, Ingrid Jenny Guldvik, Andreas Engedal, Kirsi Ketola, Wanzhong Wang, Aud Svindland et al. · 2019 · Molecular Cancer Research
5. KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy
   Jiacheng Guo, Li Ni, Qiuli Liu, Zongyao Hao, Guanghui Zhu, Xuege Wang, Hanling Wang, Qiang Pan‐Hammarström, Beitao Xu, Ying Han et al. · 2025 · Cancer Cell
6. Signaling Pathways That Control Apoptosis in Prostate Cancer
   Amaal Abdulraqeb Ali, George Kulik · 2021 · Cancers
7. Novel Strategies for Treating Castration-Resistant Prostate Cancer
   David Ka-Wai Leung, Peter Ka‐Fung Chiu, Chi‐Fai Ng, Jeremy Yuen‐Chun Teoh · 2021 · Biomedicines
8. Defining cellular population dynamics at single-cell resolution during prostate cancer progression
   Alexandre A. Germanos, Sonali Arora, Ye Zheng, Erica T. Goddard, Ilsa M. Coleman, Anson T. Ku, Scott C. Wilkinson, Hanbing Song, Nicholas J. Brady, Robert A. Amezquita et al. · 2022 · eLife
9. Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis
   Zhi Xiong, Shun-Li Yu, Zhaoxiang Xie, Ruilin Zhuang, Shirong Peng, Qiong Wang, Ze Gao, Bingheng Li, Junjia Xie, Hai Wei Huang et al. · 2024 · iScience
10. BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity
    Daniel Westaby, Juan M. Jiménez‐Vacas, Ines Figueiredo, Jan Rekowski, Claire Pettinger, Bora Gürel, Arian Lundberg, Denisa Bogdan, Lorenzo Buroni, Antje Neeb et al. · 2024 · Journal of Clinical Investigation
11. The Bone Microenvironment in Prostate Cancer Metastasis
    Anthony DiNatale, Alessandro Fatatis · 2019 · Advances in experimental medicine and biology
12. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy
    Mesude Bicak, Katharina Lückerath, Teja Muralidhar Kalidindi, Michael E. Phelps, Sven‐Erik Strand, Michael J. Morris, Caius G. Radu, Robert D. Damoiseaux, Mari T. Peltola, Norbert T. Peekhaus et al. · 2020 · Proceedings of the National Academy of Sciences
13. CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition
    Mitchell G. Lawrence, Laura H. Porter, Nicholas Choo, David William Pook, Jeremy Grummet, Carmel Jo Pezaro, Shahneen Kaur Sandhu, Susanne Ramm, Jennii Luu, Andrew Bakshi et al. · 2021 · Molecular Cancer Therapeutics
14. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
    Estefanía Labanca, Jun Yang, Peter D.A. Shepherd, Xinhai Wan, Michael W. Starbuck, Leah D. Guerra, Nicolás Anselmino, Juan Antonio Bizzotto, Jiabin Dong, Arul M. Chinnaiyan et al. · 2021 · European Urology Oncology
15. Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer
    Samuel P. Pitzen, Amber Rudenick, Yinjie Qiu, Weijie Zhang, Sarah A. Munro, Braedan M. McCluskey, Colleen L. Forster, Hannah E. Bergom, Atef Mir Ali, Ella Boytim et al. · 2025 · Proceedings of the National Academy of Sciences
16. Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
    Tomoyuki Makino, Kouji Izumi, Atsushi Mizokami · 2021 · Biomedicines
17. Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer
    Thomas Bello, Claudia Paindelli, Luis Antonio Díaz-Gómez, Anthony J. Melchiorri, Antonios G. Mikos, Peter S. Nelson, Eleonora Dondossola, Taranjit S. Gujral · 2021 · Proceedings of the National Academy of Sciences
18. Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells
    Martin K. Bakht, John J. Hayward, Farsheed Shahbazi‐Raz, Magdalena Skubal, Ryo Tamura, Keith Franklin Stringer, Daniel L. Meister, Varadha Balaji Venkadakrishnan, Hui Xue, Adam Pillon et al. · 2022 · Proceedings of the National Academy of Sciences
19. Retinoblastoma Protein Paralogs and Tumor Suppression
    Mauricio Flores, David W. Goodrich · 2022 · Frontiers in Genetics
20. RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway
    Feifei Sun, Xinpei Wang, Jing Hu, Junmei Liu, Xin Wang, Wenqiao Jia, Zeyuan Yu, Lin Gao, Baokai Dou, Ru Zhao et al. · 2022 · Oncogene
21. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer
    Paige M. Glumac, Joseph P. Gallant, Mariya Shapovalova, Yingming Li, Paari J Murugan, Shilpa Gupta, Ilsa M. Coleman, Peter S. Nelson, Scott M. Dehm, Aaron Matthew LeBeau · 2019 · Clinical Cancer Research
22. BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer
    Daniel J. Coleman, Lina Gao, Carly J. King, Jacob A. Schwartzman, Joshua A. Urrutia, Archana Sehrawat, Junior Tayou, Ariel I. Balter, Julja Burchard, Kami Chiotti et al. · 2019 · Oncogene
23. The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression
    Zhenghong Li, Carrie Qi Sun, Sijia Tao, Adeboye O. Osunkoya, Rebecca S. Arnold, John A. Petros, Xiongbing Zu, Carlos S. Moreno · 2020 · Translational Oncology
24. De novo neuroendocrine transdifferentiation in primary prostate cancer–a phenotype associated with advanced clinico-pathologic features and aggressive outcome
    Eman Abdulfatah, Zachery Roger Reichert, Matthew S. Davenport, Arul M. Chinnaiyan, Vipulkumar Dadhania, Xiaoming Wang, Rahul Mannan, Lakshmi Priya Kunju, Brent K. Hollenbeck, Jeffrey Scott Montgomery et al. · 2021 · Medical Oncology
25. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies
    Hwang, Justin H, Arafeh, Rand, Seo, Ji-Heui, Baca, Sylvan C, Ludwig, Megan, Arnoff, Taylor E, Sawyer, Lydia, Richter, Camden, Tape, Sydney, Bergom, Hannah E et al. · 2022 · eLife
26. LSD1: A single target to combat lineage plasticity in lethal prostate cancer
    Leigh Ellis, Massimo F. Loda · 2018 · Proceedings of the National Academy of Sciences
27. Role of Specialized Composition of SWI/SNF Complexes in Prostate Cancer Lineage Plasticity
    Joanna Cyrta, Anke Augspach, Maria Rosaria De Filippo, Davide Prandi, Phillip Thienger, Matteo Benelli, Victoria Cooley, Rohan Bareja, David C. Wilkes, Sung‐Suk Chae et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
28. OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer
    Daisuke Obinata, Daigo Funakoshi, Ken‐ichi Takayama, Makoto Hara, Birunthi Niranjan, Linda Teng, Mitchell G. Lawrence, Renea A. Taylor, Gail Petuna Risbridger, Yutaka Suzuki et al. · 2022 · Scientific Reports
29. LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer
    Fei Li, Pengfei Dai, Huili Shi, Yajuan Zhang, Juan He, Anuradha Gopalan, Dan Li, Yu Chen, Yarui Du, Guoliang Xu et al. · 2025 · Cell Research
30. Fibroblast growth factors signaling in bone metastasis
    Estefanía Labanca, Elba Susana Vazquez, Paul Gettys Corn, Justin M. Roberts, Fen Wang, Christopher J. Logothetis, Nora Maria Navone · 2020 · Endocrine Related Cancer
31. Androgen receptor enhancer amplification in matched patient‐derived xenografts of primary and castrate‐resistant prostate cancer
    Laura H. Porter, Andrew Bakshi, David William Pook, Ashlee K. Clark, David R. Clouston, John Kourambas, MURAL Investigators, David L. Goode, Gail Petuna Risbridger, Renea A. Taylor et al. · 2021 · The Journal of Pathology
32. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth
    Michael D. Nyquist, Lisa S. Ang, Alexandra N. Corella, Ilsa M. Coleman, Michael P. Meers, Anthony J. Christiani, Cordell Pierce, Derek H. Janssens, Hannah E. Meade, Arnab Bose et al. · 2021 · Journal of Clinical Investigation
33. Clinical, pathologic, and molecular features of amphicrine prostate cancer
    Laura S Graham, Michael C. Haffner, Erolcan Sayar, Agnes M. Gawne, Michael Thomas Schweizer, Colin C. Pritchard, Ilsa M. Coleman, Peter S. Nelson, Evan Y. Yu · 2023 · The Prostate
34. Characterization of HOXB13 expression patterns in localized and metastatic castration‐resistant prostate cancer
    Radhika A. Patel, Erolcan Sayar, Ilsa Coleman, Martine P. Roudier, Brian P. Hanratty, Jin‐Yih Low, Neha Jaiswal, Azra Ajkunic, Ruth F. Dumpit, Caner Ercan et al. · 2023 · The Journal of Pathology
35. Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer
    Johnny R. Ramroop, Mark N. Stein, Justin M. Drake · 2018 · Frontiers in Oncology
36. Epigenetic reprogramming: A key mechanism driving therapeutic resistance
    Anjali V. Sheahan, Leigh Ellis · 2018 · Urologic Oncology Seminars and Original Investigations
37. Fibroblast Growth Factor Family in the Progression of Prostate Cancer
    Jun Teishima, Tetsutaro Hayashi, Hirotaka Nagamatsu, Koichi Shoji, Hiroyuki Shikuma, Ryoken Yamanaka, Yohei Sekino, Keisuke Goto, Shogo Inoue, Akio Matsubara · 2019 · Journal of Clinical Medicine
38. Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors
    Vindhya Udhane, Cristina Maranto, David T. Hoang, Lei Gu, Andrew M. Erickson, Savita Devi, Pooja G. Talati, Anjishnu Banerjee, Kenneth A. Iczkowski, Kenneth M. Jacobsohn et al. · 2019 · Molecular Cancer Therapeutics
39. PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancer
    Chun‐Yu Liu, Jiawei Chen, Yukun Cong, Kang Chen, Haoran Li, Qingliu He, Chen Liang, Yarong Song, Yifei Xing · 2024 · Cancer Letters
40. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer
    Rahul Raj Aggarwal, Gustavo Rubio Romero, Verena Friedl, Alana S. Weinstein, Adam Foye, Jiaoti Huang, Felix Yi-Chung Feng, Joshua M. Stuart, Eric Jay Small · 2020 · Prostate Cancer and Prostatic Diseases
41. Oncogenic ACSM1 in prostate cancer is through metabolic and extracellular matrix-receptor interaction signaling pathways.
    Yongchen Guo, Chunna Ren, Wentao Huang, Wancai Yang, Yonghua Bao · 2022 · PubMed Central
42. Molecular and metabolic alterations of 2,3-dihydroquinazolin-4(1H)-one derivatives in prostate cancer cell lines
    Lina A. Dahabiyeh, Wafa Hourani, Wesam Darwish, Farah Hudaib, Bashaer Abu‐Irmaileh, Pran Kishore Deb, Katharigatta Narayanaswamy Venugopala, Viresh Mohanlall, Rana Abu‐Dahab, Mohammad Harb Semreen et al. · 2022 · Scientific Reports
43. Yin Yang 1 promotes the neuroendocrine differentiation of prostate cancer cells via the non‐canonical WNT pathway (FYN/STAT3)
    Rui‐ji Liu, Zhipeng Xu, Xiang Huang, Bin Xu, Ming Chen · 2023 · Clinical and Translational Medicine
44. hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen
    Jennifer A. Fraser, Joseph E. Sutton, Saba Tazayoni, Isla Bruce, Amy V. Poole · 2019 · Scientific Reports
45. Phagocytosis-initiated tumor hybrid cells acquire a c-Myc-mediated quasi-polarization state for immunoevasion and distant dissemination
    Chih‐Wei Chou, Chia‐Nung Hung, Cheryl Hsiang-Ling Chiu, Xi Tan, Meizhen Chen, Chien‐Chin Chen, Moawiz Saeed, Che‐Wei Hsu, Michael Andre Liss, Chiou‐Miin Wang et al. · 2023 · Nature Communications
46. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer
    Sumaira Sardar, Christopher M. McNair, Lakshmi Ravindranath, Saswati N. Chand, Wei Yuan, Denisa Bogdan, Jon C. Welti, Adam Sharp, Natalie K. Ryan, Liam A Knudsen et al. · 2024 · Oncogene
47. Lineage plasticity-mediated therapy resistance in prostate cancer
    Haojie Huang, Alexandra M. Blee · 2018 · Asian Journal of Andrology
48. Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models
    Jinny Sun, Robert Bok, Justin Delos Santos, Deepti Upadhyay, Romelyn Delos Santos, Shubhangi Agarwal, Mark Van Criekinge, Daniel B. Vigneron, Rahul Raj Aggarwal, Donna M. Peehl et al. · 2021 · Metabolites
49. Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?
    Paul Beinhoff, Lavannya Sabharwal, Vindhya Udhane, Cristina Maranto, Peter S. LaViolette, Kenneth M. Jacobsohn, Susan Tsai, Kenneth A. Iczkowski, Liang Wang, William Adrian Hall et al. · 2021 · Cancers
50. The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance
    Che‐Yuan Hu, Kuan‐Yu Wu, Tsung-Yen Lin, Chien‐Chin Chen · 2021 · International Journal of Molecular Sciences
51. The androgen receptor messenger RNA: what do we know?
    Eviania Likos, Asmita Bhattarai, Crystal M. Weyman, Girish C. Shukla · 2022 · RNA Biology
52. Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness
    Xiaozhuo Liu, Wen Jess Li, Igor J. Puzanov, David W. Goodrich, Gurkamal S. Chatta, Dean G. Tang · 2022 · Essays in Biochemistry
53. Modulating the Activity of Androgen Receptor for Treating Breast Cancer
    Chanping You, Ho Tsoi, Ellen P.S. Man, Man‐Hong Leung, US Khoo · 2022 · International Journal of Molecular Sciences
54. Tumor cell heterogeneity and resistance; report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting
    Andrea K. Miyahira, Robert Benjamin Den, Maria Isabel Carlo, Renée de Leeuw, Thomas A. Hope, Fatima H. Karzai, Rana R. McKay, Simpa Samuel Salami, Jonathan W. Simons, Kenneth J. Pienta et al. · 2018 · The Prostate
55. Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer
    Lingfan Xu, Junyi Chen, Weipeng Liu, Chang Yin Liang, Hailiang Hu, Jiaoti Huang · 2018 · Asian journal of urology
56. Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion
    Arja Kaipainen, Ailin Zhang, Rui M. Gil da Costa, Jared M. Lucas, Brett T. Marck, Alvin M. Matsumoto, Colm M. Morrissey, Lawrence D. True, Elahe A. Mostaghel, Peter S. Nelson · 2019 · The Prostate
57. Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling
    Gauri Shishodia, Sweaty Koul, Hari K. Koul · 2019 · The Prostate
58. Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells
    Abrar Samiea, Jeff S. J. Yoon, Christopher John Ong, Amina Zoubeidi, Thomas C. Chamberlain, Alice Mui · 2020 · Prostate Cancer
59. From Therapy Resistance to Targeted Therapies in Prostate Cancer
    Filipa Moreira‐Silva, Rui Henrique, Cármen Jerónimo · 2022 · Frontiers in Oncology
60. Modeling prostate cancer: What does it take to build an ideal tumor model?
    Chun‐Wai Mai, Kok‐Yong Chin, Lian Chee Foong, Kok-Lun Pang, Bin Yu, Yu Shu, Sisi Chen, Soon‐Keng Cheong, Chee Wai Chua · 2022 · Cancer Letters
61. Endocrine and paracrine characteristics of neuroendocrine prostate cancer
    Tarana Arman, Peter S. Nelson · 2022 · Frontiers in Endocrinology
62. Epithelial-to-Mesenchymal Transition-Related Markers in Prostate Cancer: From Bench to Bedside
    Samantha Gogola, Michael Rejzer, Hisham F. Bahmad, Wassim G. Abou-Kheir, Yumna Omarzai, Robert Poppiti · 2023 · Cancers
63. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer
    Miika Sainio, Tapio Visakorpi, Teemu T. Tolonen, Joanna M. Ilvesaro, G. Steven Bova · 2018 · Pathology - Research and Practice
64. Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment
    J. Ko, April N. Meyer, Martin Haas, Daniel J. Donoghue · 2021 · Oncotarget
65. RETRACTED ARTICLE: NSD2 targeting reverses plasticity and drug resistance in prostate cancer
    Jia J. Li, Alessandro Vasciaveo, Dimitris Karagiannis, Zhen Sun, Kristjan H. Gretarsson, Xiao Chen, Ouathek Ouerfelli, Fabio Socciarelli, Ziv Frankenstein, Hanyang Dong et al. · 2025 · Nature · Retracted
66. RELA is sufficient to mediate interleukin‐1 repression of androgen receptor expression and activity in an LNCaP disease progression model
    Shayna Elizabeth Thomas-Jardin, Haley Dahl, Mohammed Kanchwala, Freedom Ha, Joan Jacob, Reshma Soundharrajan, Monica Bautista, Afshan Fathima Nawas, Dexter J. Robichaux, Ragini M. Mistry et al. · 2019 · The Prostate
67. Strategic Advances in Combination Therapy for Metastatic Castration-Sensitive Prostate Cancer: Current Insights and Future Perspectives
    Whi‐An Kwon, Yong Sang Song, Min-Kyung Lee · 2024 · Cancers
68. Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy
    William Nathaniel Brennen, John T. Isaacs · 2017 · Cancer Cell
69. Engineering Prostate Cancer from Induced Pluripotent Stem Cells—New Opportunities to Develop Preclinical Tools in Prostate and Prostate Cancer Studies
    Anastasia C. Hepburn, Clive Sims, Adriana Buskin, Rakesh Heer · 2020 · International Journal of Molecular Sciences
70. Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer
    Shankha Subhra Chatterjee, Juan F. Linares, Tania Cid-Diaz, Ángeles Durán, Mohd. Imran K. Khan, Marta Osrodek, Nicholas J. Brady, Miguel Reina‐Campos, Antonio Marzio, Varadha Balaji Venkadakrishnan et al. · 2024 · Nature Communications
71. Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer
    Peder R. Braadland, Alfonso Urbanucci · 2019 · Endocrine Related Cancer
72. Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer
    Nader Al-Nakouzi, Chris Kedong Wang, Htoo Zarni Oo, Irina Nelepcu, Nada Lallous, Charlotte B. Spliid, Nastaran Khazamipour, Joey Lo, Sarah Truong, Colin C. Collins et al. · 2022 · Nature Communications
73. Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation
    Cheng Zou, Wenchao Li, Yuanzhen Zhang, Ninghan Feng, Saisai Chen, Lianlian Yan, Qinju He, Kai Wang, Wenjun Li, Yingying Li et al. · 2024 · Science Advances
74. Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes
    Matthew Utter, Sohag Chakraborty, Limor Goren, Lucas Feuser, Yuan‐Shan Zhu, David A. Foster · 2018 · Cancer Letters
75. Bipotent Progenitors Do Not Require Androgen Receptor for Luminal Specification during Prostate Organogenesis
    Maho Shibata, Nusrat J Epsi, Shouhong Xuan, Antonina Mitrofanova, Michael M. Shen · 2020 · Stem Cell Reports
76. Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer
    Daniel Westaby, Paul Vincent Viscuse, Rahul Ravilla, Maria D. Fenor de la Maza, Andrew Warren Hahn, Adam Sharp, Johann Sebastian De Bono, Ana M. Aparicio, Mark T. Fleming · 2021 · American Society of Clinical Oncology Educational Book
77. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes
    Ninghui Mao, Dong Gao, Wenhuo Hu, Haley Hieronymus, Shangqian Wang, Young Sun Lee, Cindy Lee, Danielle Choi, Anuradha Gopalan, Yu Chen et al. · 2019 · Molecular Cancer Therapeutics
78. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer
    Zheng Zhang, Yi Qin, Shunrong Ji, Wenyan Xu, Mengqi Liu, Qiangsheng Hu, Ye Zeng, Guixiong Fan, Xianjun Yu, Wensheng Liu et al. · 2021 · Acta Biochimica et Biophysica Sinica
79. FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer
    Paola Chiodelli, Daniela Coltrini, Marta Turati, Marianna Cerasuolo, Federica Maccarinelli, Sara Rezzola, Elisabetta Grillo, Arianna Giacomini, Sara Taranto, Silvia Mussi et al. · 2021 · Cancer Letters
80. De novo neuroendocrine features in prostate cancer
    Eman Abdulfatah, Samson W. Fine, Tamara Levin Lotan, Rohit Mehra · 2022 · Human Pathology
81. RETRACTED: ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer
    Nakisa Tabrizian, Shaghayegh Nouruzi, Cassandra Jingjing Cui, Maxim Kobelev, Takeshi Namekawa, Ishana Lodhia, Amina Talal, Olena Sivak, Dwaipayan Ganguli, Amina Zoubeidi · 2023 · Cell Reports · Retracted
82. Glucocorticoid receptor action in prostate cancer: the role of transcription factor crosstalk
    Johannes Hiltunen, Laura Helminen, Ville Paakinaho · 2024 · Frontiers in Endocrinology
83. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer
    Dingxie Liu · 2020 · Cellular Oncology
84. Increased nuclear factor I/B expression in prostate cancer correlates with AR expression
    Jagpreet Singh Nanda, Wisam N. Awadallah, Sarah E. Kohrt, Petra Popovics, Justin Cates, Janni Mirosevich, Peter E. Clark, Giovanna A. Giannico, Magdalena M. Grabowska · 2020 · The Prostate
85. PIK3CG Is a Potential Therapeutic Target in Androgen Receptor–Indifferent Metastatic Prostate Cancer
    Wen-Cheng Chung, Xinchun Zhou, Azeddine Atfi, Keli Xu · 2020 · American Journal Of Pathology
86. Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence
    Haley Dahl, Mohammed Kanchwala, Shayna Elizabeth Thomas-Jardin, Amrit Sandhu, Preethi Kanumuri, Afshan Fathima Nawas, Chao Xing, Chenchu Lin, Daniel E. Frigo, Nikki Ayanna Delk · 2020 · PLoS ONE
87. Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors
    Mohamed Wishahi · 2024 · World Journal of Clinical Cases
88. Subtype and Site Specific–Induced Metabolic Vulnerabilities in Prostate Cancer
    Federica Mossa, Daniele Robesti, Sumankalai Ramachandran, Eva Corey, Mark Anton Titus, Yuqi Kang, Jianhua Zhang, Alberto Briganti, Francesco Montorsi, Christopher P. Vellano et al. · 2022 · Molecular Cancer Research
89. High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
    Marina Nasrin Sharifi, Jamie M. Sperger, Amy K. Taylor, Katharine E. Tippins, Shannon R. Reese, Viridiana Carreno, Katherine R. Kaufmann, Alex Hong Chang, Luke A. Nunamaker, Charlotte Linebarger et al. · 2025 · Cancer Discovery
90. Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network
    Ahn R. Lee, Nicole Che, Jessica M. Lovnicki, Xuesen Dong · 2018 · Frontiers in Oncology
91. Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy
    Saeed Salehin Akhand, Hao Chen, Stephen Connor Purdy, Zian Liu, Joshua Charles Anderson, Christopher Douglas Willey, Michael K. Wendt · 2021 · npj Breast Cancer
92. Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases
    Tesa Severson, Yanyun Zhu, Angelo Michael De Marzo, Tracy Jones, Jonathan W. Simons, William G. Nelson, Srinivasan Yegnasubramanian, Matthew L. Freedman, Lodewyk F.A. Wessels, Andries Marinus Bergman et al. · 2021 · Molecular Oncology
93. Prostate cancer cell heterogeneity and plasticity: Insights from studies of genetically-engineered mouse models
    Weiping Li, Michael M. Shen · 2021 · Seminars in Cancer Biology
94. Alternative RNA splicing of the GIT 1 gene is associated with neuroendocrine prostate cancer
    Ahn R. Lee, Yu Gan, Ning Xie, Varune Rohan Ramnarine, Jessica M. Lovnicki, Xuesen Dong · 2018 · Cancer Science
95. Molecular Pathology of Prostate Cancer
    İbrahim Kulaç, Martine P. Roudier, Michael C. Haffner · 2024 · Clinics in Laboratory Medicine
96. Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer
    Kei Mizuno, Sheng‐Yu Ku, Varadha Balaji Venkadakrishnan, Martin K. Bakht, Michael Sigouros, Joanna Chan, Anna Trigos, Jordan H. Driskill, Jyothi Manohar, Abigail S. King et al. · 2025 · Nature Communications
97. Perspectives on Circular RNAs as Prostate Cancer Biomarkers
    Jiajie Fang, Jianfei Qi, Xuesen Dong, Jindan Luo · 2020 · Frontiers in Cell and Developmental Biology
98. Alpha Satellite RNA Levels Are Upregulated in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer
    Sven Ljubić, Antonio Sermek, Angela Prgomet Sečan, Marin Prpić, Blanka Jakšić, Jure Murgić, Ana Fröbe, Đurđica Ugarković, Isidoro Feliciello · 2022 · Genes
99. The future of patient-derived xenografts in prostate cancer research
    Mitchell G. Lawrence, Renea A. Taylor, Georgia B. Cuffe, Lisa S. Ang, Ashlee K. Clark, David L. Goode, Laura H. Porter, Clémentine Le Magnen, Nora Maria Navone, Jack A. Schalken et al. · 2023 · Nature Reviews Urology
100. Unique Spectrum of Activating BRAF Alterations in Prostate Cancer
     Alex Chehrazi‐Raffle, Hanna Tukachinsky, Eamon Toye, Smruthy Sivakumar, Alexa Betzig Schrock, Hannah E. Bergom, Hedyeh Ebrahimi, Sumanta Kumar Pal, Tanya Barauskas Dorff, Neeraj Agarwal et al. · 2023 · Clinical Cancer Research